Sanofi (EPA:SAN) has been given a €78.00 ($90.70) price objective by research analysts at Jefferies Financial Group in a report released on Thursday, August 16th. The brokerage currently has a “neutral” rating on the stock. Jefferies Financial Group’s target price would suggest a potential upside of 17.88% from the stock’s previous close.
A number of other research analysts also recently commented on the stock. Goldman Sachs Group set a €74.00 ($86.05) price objective on shares of Sanofi and gave the company a “neutral” rating in a research report on Thursday, June 14th. Citigroup set a €93.00 ($108.14) target price on shares of Sanofi and gave the stock a “buy” rating in a report on Friday, August 10th. JPMorgan Chase & Co. set a €72.00 ($83.72) target price on shares of Sanofi and gave the stock a “neutral” rating in a report on Thursday, May 10th. Deutsche Bank set a €87.00 ($101.16) target price on shares of Sanofi and gave the stock a “buy” rating in a report on Thursday, July 19th. Finally, Credit Suisse Group set a €80.00 ($93.02) target price on shares of Sanofi and gave the stock a “buy” rating in a report on Wednesday, August 1st. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and seven have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of €79.21 ($92.11).
Shares of SAN traded down €0.06 ($0.07) during midday trading on Thursday, reaching €66.17 ($76.94). The stock had a trading volume of 6,890,000 shares, compared to its average volume of 3,050,000. Sanofi has a one year low of €63.09 ($73.36) and a one year high of €92.97 ($108.10).
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an oral immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Recommended Story: NASDAQ
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.